jag009
★★★

NJ,
2018-09-07 20:31
(1432 d 19:05 ago)

Posting: # 19251
Views: 1,799
 

 FDA Supac guidance for ER [Regulatives / Guidelines]

Hi,

Question. To support SUPAC (post approval manufacturing site change) filing for ER products, do we need to perform multimedia dissolution testings?

Thanks
John
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2018-09-09 14:04
(1431 d 01:32 ago)

@ jag009
Posting: # 19253
Views: 1,497
 

 FDA Supac guidance for ER

Hi John,

» To support SUPAC (post approval manufacturing site change) filing for ER products, do we need to perform multimedia dissolution testings?

Generally not. That’s a Level 3 Change.
See the guidance V. C. 2. b. Dissolution documentation:

In addition to application/compendial release requirements, a multipoint dissolution profile should be obtained using application/compendial test conditions for the changed drug product and the biobatch or marketed batch (unchanged drug product). Adequate sampling should be performed, for example at 1, 2, and 4 hours and every two hours thereafter until either 80% of the drug from the drug product is released or an asymptote is reached.

But don’t forget V. C. 2. c. Bioequivalence documentation:

A single-dose bioequivalence study. The bioequivalence study may be waived in the presence of an established in vitro/in vivo correlation.


Dif-tor heh smusma 🖖 [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
jag009
★★★

NJ,
2018-09-10 18:38
(1429 d 20:59 ago)

@ Helmut
Posting: # 19256
Views: 1,450
 

 FDA Supac guidance for ER

Thank Helmut!
UA Flag
Activity
 Admin contact
22,291 posts in 4,666 threads, 1,584 registered users;
online 10 (3 registered, 7 guests [including 5 identified bots]).
Forum time: Wednesday 15:37 CEST (Europe/Vienna)

There ain’t no rules around here!
We’re trying to accomplish something!    Thomas Alva Edison

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5